Worth Watching: What’s Propelling Lannett Company, Inc. to Decline So Much?

Worth Watching: What's Propelling Lannett Company, Inc. to Decline So Much?

The stock of Lannett Company, Inc. (NYSE:LCI) is a huge mover today! The stock decreased 4.12% or $1 on November 15, hitting $23.25. About 1.07 million shares traded hands. Lannett Company, Inc. (NYSE:LCI) has risen 30.59% since April 13, 2016 and is uptrending. It has outperformed by 26.66% the S&P500.
The move comes after 5 months negative chart setup for the $891.54M company. It was reported on Nov, 15 by Barchart.com. We have $21.39 PT which if reached, will make NYSE:LCI worth $71.32M less.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Buy” rating by Roth Capital on Wednesday, August 26. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) on Thursday, March 24 with “Buy” rating. As per Thursday, September 3, the company rating was maintained by Roth Capital. The firm has “Sell” rating given on Thursday, March 24 by Canaccord Genuity. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) on Friday, March 11 with “Buy” rating. Raymond James maintained Lannett Company, Inc. (NYSE:LCI) on Wednesday, August 24 with “Outperform” rating. The firm earned “Positive” rating on Tuesday, July 21 by Susquehanna. The rating was initiated by Deutsche Bank with “Hold” on Wednesday, June 29. Zacks upgraded Lannett Company, Inc. (NYSE:LCI) on Monday, September 7 to “Strong-Buy” rating. Craig Hallum upgraded the shares of LCI in a report on Thursday, February 4 to “Buy” rating.

According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”

Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.07, from 0.81 in 2016Q1. The ratio improved, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.
Moreover, Dimensional Fund Advsr Limited Partnership has 0.01% invested in Lannett Company, Inc. (NYSE:LCI) for 875,850 shares. Ameriprise Fincl has 0.01% invested in the company for 403,101 shares. Telemus Capital Limited Liability Com owns 5.85M shares or 17.26% of their US portfolio. Kennedy Capital Mngmt reported 106,822 shares or 0.05% of all its holdings. Wells Fargo Mn accumulated 0% or 155,545 shares. Moreover, Pnc Ser has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 74,546 shares. Grp Inc One Trading Limited Partnership last reported 0% of its portfolio in the stock. Northern Trust has 362,656 shares for 0% of their US portfolio. Blackrock Institutional Tru Na accumulated 0% or 689,158 shares. Coatue Mngmt Limited Company last reported 0.61% of its portfolio in the stock. Clinton Gp holds 0.02% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 16,526 shares. Moreover, Lpl Financial Llc has 0.01% invested in Lannett Company, Inc. (NYSE:LCI) for 29,661 shares. Perceptive Advsrs, a New York-based fund reported 26,670 shares. Moreover, Prudential has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 84,688 shares. Putnam Investments accumulated 0.02% or 342,618 shares.

Insider Transactions: Since August 31, 2016, the stock had 0 insider purchases, and 3 selling transactions for $416,823 net activity. Landis G. Michael sold 6,786 shares worth $226,716. The insider Maher James M. sold 1,478 shares worth $50,119.

More recent Lannett Company, Inc. (NYSE:LCI) news were published by: Fool.com which released: “Why Lannett Company, Inc. Shares Got Pummeled Today” on October 17, 2016. Also Businesswire.com published the news titled: “EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Lannett Company …” on November 07, 2016. Prnewswire.com‘s news article titled: “Lannett To Present At The Jefferies 2016 London Healthcare Conference On …” with publication date: November 09, 2016 was also an interesting one.

LCI Company Profile

Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment